BioMarin Pharmaceutical Inc (BMRN) stock
BMRNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 8/3093% above fair value
$61.43+2.92 (+4.99%)
Close on Nov 18, 2026Market cap $11.89BP/E 161.7Yield –
BioMarin Pharmaceutical revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
BioMarin Pharmaceutical's revenue for the twelve months ending Jun 30, 2026 was $3.41B, up 11.2% year over year. For fiscal 2025 it was $3.22B, up 12.9% from the year before. Over ten years it grew 13.7% a year on average. The highest annual figure on record is $3.22B in fiscal 2025.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.22B | +12.9% |
| FY2024 | Dec 31, 2024 | $2.85B | +18.0% |
| FY2023 | Dec 31, 2023 | $2.42B | +15.4% |
| FY2022 | Dec 31, 2022 | $2.10B | +13.5% |
| FY2021 | Dec 31, 2021 | $1.85B | -0.8% |
| FY2020 | Dec 31, 2020 | $1.86B | +9.2% |
| FY2019 | Dec 31, 2019 | $1.70B | +14.3% |
| FY2018 | Dec 31, 2018 | $1.49B | +13.5% |
| FY2017 | Dec 31, 2017 | $1.31B | +17.6% |
| FY2016 | Dec 31, 2016 | $1.12B | +25.5% |
| FY2015 | Dec 31, 2015 | $889.90M | +18.8% |
| FY2014 | Dec 31, 2014 | $749.28M | +36.6% |
| FY2013 | Dec 31, 2013 | $548.49M | +9.5% |
| FY2012 | Dec 31, 2012 | $500.72M | +13.5% |
| FY2011 | Dec 31, 2011 | $441.36M | +17.3% |
| FY2010 | Dec 31, 2010 | $376.27M | +15.9% |
| FY2009 | Dec 31, 2009 | $324.66M | +9.5% |
| FY2008 | Dec 31, 2008 | $296.49M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $989.71M | +19.9% |
| Q1 FY2026 | Mar 31, 2026 | $766.21M | +2.8% |
| Q4 FY2025 | Dec 31, 2025 | $874.57M | +17.0% |
| Q3 FY2025 | Sep 30, 2025 | $776.13M | +4.1% |
| Q2 FY2025 | Jun 30, 2025 | $825.41M | +15.9% |
| Q1 FY2025 | Mar 31, 2025 | $745.15M | +14.8% |
| Q4 FY2024 | Dec 31, 2024 | $747.31M | +15.6% |
| Q3 FY2024 | Sep 30, 2024 | $745.74M | +28.3% |
| Q2 FY2024 | Jun 30, 2024 | $712.03M | +19.6% |
| Q1 FY2024 | Mar 31, 2024 | $648.83M | +8.8% |
| Q4 FY2023 | Dec 31, 2023 | $646.21M | +20.2% |
| Q3 FY2023 | Sep 30, 2023 | $581.33M | +15.0% |
| Q2 FY2023 | Jun 30, 2023 | $595.28M | +11.5% |
| Q1 FY2023 | Mar 31, 2023 | $596.42M | +14.8% |
| Q4 FY2022 | Dec 31, 2022 | $537.54M | +19.5% |
| Q3 FY2022 | Sep 30, 2022 | $505.34M | +23.6% |
| Q2 FY2022 | Jun 30, 2022 | $533.80M | +6.4% |
| Q1 FY2022 | Mar 31, 2022 | $519.36M | +6.9% |
| Q4 FY2021 | Dec 31, 2021 | $449.81M | -0.5% |
| Q3 FY2021 | Sep 30, 2021 | $408.74M | -14.3% |
| Q2 FY2021 | Jun 30, 2021 | $501.69M | +16.8% |
| Q1 FY2021 | Mar 31, 2021 | $486.03M | -3.2% |
| Q4 FY2020 | Dec 31, 2020 | $452.12M | -0.5% |
| Q3 FY2020 | Sep 30, 2020 | $476.78M | +3.4% |
| Q2 FY2020 | Jun 30, 2020 | $429.49M | +10.8% |
| Q1 FY2020 | Mar 31, 2020 | $502.07M | +25.3% |
| Q4 FY2019 | Dec 31, 2019 | $454.44M | +28.7% |
| Q3 FY2019 | Sep 30, 2019 | $461.10M | +17.7% |
| Q2 FY2019 | Jun 30, 2019 | $387.76M | +4.0% |
| Q1 FY2019 | Mar 31, 2019 | $400.75M | +7.3% |
| Q4 FY2018 | Dec 31, 2018 | $353.21M | -1.4% |
| Q3 FY2018 | Sep 30, 2018 | $391.71M | +17.2% |
| Q2 FY2018 | Jun 30, 2018 | $372.85M | +17.5% |
| Q1 FY2018 | Mar 31, 2018 | $373.45M | +22.9% |
| Q4 FY2017 | Dec 31, 2017 | $358.31M | +19.4% |
| Q3 FY2017 | Sep 30, 2017 | $334.15M | +19.4% |
| Q2 FY2017 | Jun 30, 2017 | $317.45M | – |
| Q1 FY2017 | Mar 31, 2017 | $303.75M | – |
| Q4 FY2016 | Dec 31, 2016 | $300.09M | – |
| Q3 FY2016 | Sep 30, 2016 | $279.90M | – |
See a number that looks wrong?